Samantha S F Lee1, Adrienne E Fulford2, Maureen A Quinn2, Jamie Seabrook3, Irina Rajakumar4. 1. Pharmacy Department, St. Michael's Hospital, 30 Bond St, Toronto, ON, M5B 1W8, Canada. leesam@smh.ca. 2. Department of Hematology, London Health Sciences Centre, 800 Commissioners Rd E, London, ON, N6A 5W9, Canada. 3. Department of Epidemiology and Biostatistics, Western University, 1151 Richmond St, London, ON, N6A 3K7, Canada. 4. Department of Pharmacy, Alberta Health Services, Foothills Medical Centre, 1403 29 Street NW, Calgary, AB, T2N 2T9, Canada.
Abstract
PURPOSE: The purpose of this study is to evaluate the efficacy and safety of prophylactic oral levofloxacin in acute myeloid leukemia (AML) patients after receiving consolidation chemotherapy to prevent febrile neutropenia. METHODS: We conducted a retrospective chart review of 50 AML patients who were prescribed levofloxacin and 50 AML patients who were not prescribed levofloxacin post-consolidation chemotherapy between June 2006 and August 2013 at a tertiary academic medical center. The primary outcome of this study was to evaluate the effectiveness of levofloxacin in preventing hospital readmission due to febrile neutropenia. Secondary outcomes evaluated the safety of this therapy, including the rate of Clostridium difficile-associated diarrhea (CDAD) within 30 days from discharge of receiving consolidation chemotherapy and rate of fluoroquinolone resistance in positive bacterial cultures. RESULTS: Hospital readmission due to febrile neutropenia after the first consolidation cycle occurred in 42% of patients prescribed levofloxacin, as compared to 72% that were not prescribed levofloxacin (p = 0.002). This was also significantly reduced when levofloxacin was prescribed after all consolidation cycles (51.4 vs. 67%, p = 0.023). CDAD did not occur in any patient prescribed levofloxacin after the first cycle, compared to one case in those not prescribed levofloxacin. Evaluation of the impact on fluoroquinolone resistance was limited due to a paucity of fluoroquinolone susceptibilities reported. CONCLUSIONS: Prescribing oral levofloxacin post-consolidation chemotherapy in AML patients is associated with a reduction in febrile neutropenia. Further research is required to identify the impact on fluoroquinolone resistance and risk of CDAD.
PURPOSE: The purpose of this study is to evaluate the efficacy and safety of prophylactic oral levofloxacin in acute myeloid leukemia (AML) patients after receiving consolidation chemotherapy to prevent febrile neutropenia. METHODS: We conducted a retrospective chart review of 50 AMLpatients who were prescribed levofloxacin and 50 AMLpatients who were not prescribed levofloxacin post-consolidation chemotherapy between June 2006 and August 2013 at a tertiary academic medical center. The primary outcome of this study was to evaluate the effectiveness of levofloxacin in preventing hospital readmission due to febrile neutropenia. Secondary outcomes evaluated the safety of this therapy, including the rate of Clostridium difficile-associated diarrhea (CDAD) within 30 days from discharge of receiving consolidation chemotherapy and rate of fluoroquinolone resistance in positive bacterial cultures. RESULTS: Hospital readmission due to febrile neutropenia after the first consolidation cycle occurred in 42% of patients prescribed levofloxacin, as compared to 72% that were not prescribed levofloxacin (p = 0.002). This was also significantly reduced when levofloxacin was prescribed after all consolidation cycles (51.4 vs. 67%, p = 0.023). CDAD did not occur in any patient prescribed levofloxacin after the first cycle, compared to one case in those not prescribed levofloxacin. Evaluation of the impact on fluoroquinolone resistance was limited due to a paucity of fluoroquinolone susceptibilities reported. CONCLUSIONS: Prescribing oral levofloxacin post-consolidation chemotherapy in AMLpatients is associated with a reduction in febrile neutropenia. Further research is required to identify the impact on fluoroquinolone resistance and risk of CDAD.
Authors: W V Kern; K Klose; A S Jellen-Ritter; M Oethinger; J Bohnert; P Kern; S Reuter; H von Baum; R Marre Journal: Eur J Clin Microbiol Infect Dis Date: 2005-02 Impact factor: 3.267
Authors: Lindsey Robert Baden; Sankar Swaminathan; Michael Angarone; Gayle Blouin; Bernard C Camins; Corey Casper; Brenda Cooper; Erik R Dubberke; Ashley Morris Engemann; Alison G Freifeld; John N Greene; James I Ito; Daniel R Kaul; Mark E Lustberg; Jose G Montoya; Ken Rolston; Gowri Satyanarayana; Brahm Segal; Susan K Seo; Shmuel Shoham; Randy Taplitz; Jeffrey Topal; John W Wilson; Karin G Hoffmann; Courtney Smith Journal: J Natl Compr Canc Netw Date: 2016-07 Impact factor: 11.908
Authors: Giampaolo Bucaneve; Alessandra Micozzi; Francesco Menichetti; Pietro Martino; M Stella Dionisi; Giovanni Martinelli; Bernardino Allione; Domenico D'Antonio; Maurizio Buelli; A Maria Nosari; Daniela Cilloni; Eliana Zuffa; Renato Cantaffa; Giorgina Specchia; Sergio Amadori; Francesco Fabbiano; Giorgio Lambertenghi Deliliers; Francesco Lauria; Robin Foà; Albano Del Favero Journal: N Engl J Med Date: 2005-09-08 Impact factor: 91.245
Authors: Alison G Freifeld; Eric J Bow; Kent A Sepkowitz; Michael J Boeckh; James I Ito; Craig A Mullen; Issam I Raad; Kenneth V Rolston; Jo-Anne H Young; John R Wingard Journal: Clin Infect Dis Date: 2011-02-15 Impact factor: 9.079
Authors: Christopher R Flowers; Jerome Seidenfeld; Eric J Bow; Clare Karten; Charise Gleason; Douglas K Hawley; Nicole M Kuderer; Amelia A Langston; Kieren A Marr; Kenneth V I Rolston; Scott D Ramsey Journal: J Clin Oncol Date: 2013-01-14 Impact factor: 44.544
Authors: Katherine A Simondsen; Michael P Reed; Mary S Mably; Yang Zhang; Walter L Longo Journal: J Oncol Pharm Pract Date: 2012-11-26 Impact factor: 1.809
Authors: H Imran; I M Tleyjeh; C A S Arndt; L M Baddour; P J Erwin; C Tsigrelis; N Kabbara; V M Montori Journal: Eur J Clin Microbiol Infect Dis Date: 2007-10-16 Impact factor: 3.267
Authors: Annika Y Classen; Larissa Henze; Marie von Lilienfeld-Toal; Georg Maschmeyer; Michael Sandherr; Luisa Durán Graeff; Nael Alakel; Maximilian Christopeit; Stefan W Krause; Karin Mayer; Silke Neumann; Oliver A Cornely; Olaf Penack; Florian Weißinger; Hans-Heinrich Wolf; Jörg Janne Vehreschild Journal: Ann Hematol Date: 2021-04-13 Impact factor: 3.673
Authors: Stelios Chrysostomou; Rajat Roy; Filippo Prischi; Lucksamon Thamlikitkul; Kathryn L Chapman; Uwais Mufti; Robert Peach; Laifeng Ding; David Hancock; Christopher Moore; Miriam Molina-Arcas; Francesco Mauri; David J Pinato; Joel M Abrahams; Silvia Ottaviani; Leandro Castellano; Georgios Giamas; Jennifer Pascoe; Devmini Moonamale; Sarah Pirrie; Claire Gaunt; Lucinda Billingham; Neil M Steven; Michael Cullen; David Hrouda; Mathias Winkler; John Post; Philip Cohen; Seth J Salpeter; Vered Bar; Adi Zundelevich; Shay Golan; Dan Leibovici; Romain Lara; David R Klug; Sophia N Yaliraki; Mauricio Barahona; Yulan Wang; Julian Downward; J Mark Skehel; Maruf M U Ali; Michael J Seckl; Olivier E Pardo Journal: Sci Transl Med Date: 2021-07-14 Impact factor: 17.956